

MSL Companion

A case study on how to use LLMs to empower MSL teams at Bristol Myers Squibb.

Oct 18, 2024

Jose de la Garza

Objectives

Identify a solution that uses LLMs to inform, train and empower MSL teams by using custom data.

Create a prototype that will showcase the benefits of an MSL companion to drive further investment in Al.

MSL Companion


MSL Companion can make indication information available at the fingertips.

A web-based solution using the latest technology:

- Python
- Streamlit.io, a Python library to build data apps.


... and the latest LLM modeling:


- OpenAl GPT-4o.
- Prompt tuning.
- RAG (Retrieval-Augmented Generation) document search, top 17 drugs manufactured by BMS.




Demo & Code Review


MSL Companion vs ChatGPT: Results Are More Relevant to BMS MSL team





MSL Companion vs ChatGPT: Limited Breath of Answers Improves Reliability





MSL Companion vs ChatGPT Mitigate Incorrect Answers (Hallucination)



Melanoma


- adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1)
- for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2)

Yes, OPDIVO is approved for pediatric patients 12 years and older for the treatment of:

- Unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1)
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab. (1.11)

Colorectal Cancer

 adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab.^a (1.11)



For younger pediatric natients (under 12) or for cancers other than Hodgkin lymphoma

Classical Hodgkin Lymphoma (cHL)

- adult patients with classical Hodgkin lymphoma that has relapsed or progressed after^a: (1.8)
 - autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or
 - 3 or more lines of systemic therapy that includes autologous HSCT.

Future Potential Enhancements

- Enable web links to each source PI.
- Enable other information in the PI.
- Enable other information relevant to MSLs, including proprietary information.
- Enable open-source models like Llama that can be hosted in-house to limit the risk of proprietary data being sent externally.

Thank you

Jose de la Garza jose.delagarza@gmx.net

